Skip to main navigation menu Skip to main content Skip to site footer
FrancoAngeli Journals

Saggi, Studi e Ricerche

No. 59 (2022)

State of the art of the collaboration among Addiction Department, Primary care Physicians, Central Hospital and Territorial Pharmacy referring to the Azienda Sanitaria Universitaria Giuliana-Isontina: inferences from an analysis of the first quarter of 20

DOI
https://doi.org/10.3280/mis59-2022oa14827
Submitted
dicembre 16, 2022
Published
2023-02-15

Abstract

The involvement of Primary Care Physicians (PCP) in the treatment of patients with Opioid Use Disorder (DUO) is pivotal in promoting customized care and patient’s empowerment.  This study aimed to infer the efficiency of the long-standing collaboration among of Addiction Department (AD) of Trieste, PCP and pharmacies, particularly focusing on both prescription appropriateness and adequate medical supervision and toxicological tracking during the first quarter of 2022 within the Trieste area .  Data concerning clinical and toxicological condition and prescription appropriateness of 58 patients attending the AD for Personalized Treatment Plan (PTP) issue and referring to 26 different PCP for PTP-related agonist treatment prescription were analysed.  Agonist prescription was proper in 81.0% of cases, the PTP was regularly issued by AD specialist in 89.7% of cases and urinary testing was performed ≥ 2 times monthly by patients showing better clinical stabilization and representing 39.7% of the whole sample.

This research suggests that the best clinical outcome is achieved when patients with DUO have appropriate prescription and toxicological monitoring by means of a multidisciplinary teamwork.  Therefore, information exchange among different professionals should be enhanced as to improve the quality of the assistance offered by public services as well as the early detection of critical cases and inadequate prescriptions of opioid agonists.

References

  1. Balestra R. (2007). Il coinvolgimento dei medici di medicina generale nella cura dei pazienti tossicodipendenti a Trieste. FeDerSerD Informa, 6: 12-14.
  2. Balestra R., Conti G. (2008). L’affido di metadone nei Ser.T. e i medici di medicina generale: la collaborazione a Trieste. FeDerSerD Informa, 9: 14-16.
  3. Binz T.M., Baumgartner M.R. (2016). Hair Analysis for the Retrospective and Prospective Consume-Monitoring: Substance Abuse, Abstinence – and Compliance Control. Praxis, 105(1): 17-21.
  4. Boffin N., Antoine J., Moreels S., Wanyama S., De Ridder K., Peremans L., Vanmeerbeek M., Van Casteren V. (2016). General practice patients treated for substance use problems: a cross-national observational study in Belgium. BMC Public Health, 16: 1235.
  5. Cochran G., Bruneau J., Cox N., Gordon A.J. (2020). Medication treatment for opioid use disorder and community pharmacy: expanding care during a national epidemic and global pandemic. Subst. Abus., 41(3): 269-274.
  6. Feroni I., Peretti-Watel P., Masut A., Coudert C., Paraponaris A., Obadia Y. (2005). French general practitioners’ prescribing highdosage
  7. buprenorphine maintenance treatment: is the existing training (good) enough? Addict. Behav., 30(1): 187-91.
  8. Fraeyman J., Symons L., Van Royen P., Van Hal G., Peremans L. (2016). How to overcome hurdles in opiate substitution treatment? A qualitative study with general practitioners in Belgium. Eur. J. Gen. Pract., 22(2): 134-140.
  9. Guy W. (1976). Clinical Global Impressions. ECDEU Assessment Manual for Pyschopharmacology – Revised. Rockville, MD: US Department of Health, Education and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration.
  10. Klimas J., Egan M., Tobin H., Coleman N., Bury G. (2015). Development and process evaluation of an educational intervention for overdose prevention and naloxone distribution by general practice trainees. BMC Med. Educ., 15: 206.
  11. Lagisetty P., Klasa K., Bush C., Heisler M., Chopra V., Bohnert A. (2017). Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS One, 12(10): e0186315.
  12. Landreat M.G., Rozaire C., Guillet J.Y., Vigneau C.V., Le Reste J.Y., Bronnec M.G. (2015). French experience with Buprenorphine: do physicians follow the guidelines? PLoS One, 10(10): e0137708.
  13. Mandt I., Anne Marie Horn A.M., Ekedahl A., Granas A.G. (2010). Community pharmacists’ prescription intervention practices – exploring variations in practice in Norwegian pharmacies. Res Social and Adm. Pharm., 6(1): 6-17.
  14. Niles J.K., Gudin J., Radcliff J., Kaufman W. (2021). The opioid epidemic within the Covid-19 pandemic: drug testing in the 2020. Popul. Health Manag., 24: S1 43-51.
  15. Palamar J.J., Le Austin., Guarino H., Gelabert P.M. (2019). A comparison of the utility of urine and hair testing in detecting selfreported drug use among young adult opioid users. Drug Alcohol Depend., 200: 161-167.
  16. Rouillon M., Laporte C., Ingrand P., Castéra P., Di Patrizio P., Messaadi N., Binder P., Dupouy J. (2021). Perceptions, professional responsibility and management experiences patients with alcohol, tobacco and opioid use disorder by residents in general practice and teaching general practitioners. Eur. J. Gen. Pract., 27(1): 77-82.
  17. Van Hout M.C., Crowley D., McBride A., Delargy I. (2018). Optimising treatment in opioid dependency in primary care: results from national key stakeholder and expert focus group in Ireland. BMC Fam. Pract., 19: 103.
  18. Wazaify M., Hughes C.M., McElnay J.C. (2006). The implementation of a harm minimization model for the identification and treatment of over-the-counter drug misuse and abuse in community pharmacies in Northern Ireland. Patient Educ. Couns., 64(1-3): 136-41.
  19. Wilson H.H.K., Schulz M., Mills L., Lintzeris N. (2022). Feasibility and outcomes of a general practice and specialist alcohol and other drug collaborative care program in Sydney, Australia. Austr. J. Prim. Health, 28(2): 158-163.

Metrics

Metrics Loading ...